Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Calvin J Cohen

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
HIV Clinical Trials|April 17, 2007
Pilot study of a novel short-cycle antiretroviral treatment interruption strategy: 48-week results of the five-days-on, two-days-off (FOTO) studyCalvin J Cohen, Amy E Colson, Alexander G Sheble-Hall, et al.
BMC Infectious Diseases|April 12, 2005
Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimensSusan Swindells, Calvin J Cohen, Daniel S Berger, et al.
BMC Complementary and Alternative Medicine|February 1, 2012
Impact of Tai Chi exercise on multiple fracture-related risk factors in post-menopausal osteopenic women: a pilot pragmatic, randomized trialPeter M Wayne, Douglas P Kiel, Julie E Buring, et al.
AIDS Care|October 22, 2015
Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatmentEd L Wilkins, Calvin J Cohen, Benoit Trottier, et al.
Plos One|May 13, 2016
Relevance of Interleukin-6 and D-Dimer for Serious Non-AIDS Morbidity and Death among HIV-Positive Adults on Suppressive Antiretroviral TherapyBirgit Grund, Jason V Baker, Steven G Deeks, et al.
AIDS (London, England)|March 2, 2002
A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapyCalvin J Cohen, Susan Hunt, Michael Sension, et al.
Lancet (London, England)|July 19, 2011
Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trialCalvin J Cohen, Jaime Andrade-Villanueva, Bonaventura Clotet, et al.
Pharmacotherapy|February 26, 2008
Short-term safety and tolerability of a once-daily fixed-dose abacavir-lamivudine combination versus twice-daily dosing of abacavir and lamivudine as separate components: findings from the ALOHA studyCalvin J Cohen, Marshall Kubota, Philip S Brachman, et al.
BMC Musculoskeletal Disorders|March 3, 2010
Tai Chi for osteopenic women: design and rationale of a pragmatic randomized controlled trialPeter M Wayne, Julie E Buring, Roger B Davis, et al.
The Journal of Infectious Diseases|May 14, 2008
Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study, Sean Emery, Jacqueline A Neuhaus, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
HIV Clinical Trials|April 17, 2007
Pilot study of a novel short-cycle antiretroviral treatment interruption strategy: 48-week results of the five-days-on, two-days-off (FOTO) studyCalvin J Cohen, Amy E Colson, Alexander G Sheble-Hall, et al.
BMC Infectious Diseases|April 12, 2005
Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimensSusan Swindells, Calvin J Cohen, Daniel S Berger, et al.
BMC Complementary and Alternative Medicine|February 1, 2012
Impact of Tai Chi exercise on multiple fracture-related risk factors in post-menopausal osteopenic women: a pilot pragmatic, randomized trialPeter M Wayne, Douglas P Kiel, Julie E Buring, et al.
AIDS Care|October 22, 2015
Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatmentEd L Wilkins, Calvin J Cohen, Benoit Trottier, et al.
Plos One|May 13, 2016
Relevance of Interleukin-6 and D-Dimer for Serious Non-AIDS Morbidity and Death among HIV-Positive Adults on Suppressive Antiretroviral TherapyBirgit Grund, Jason V Baker, Steven G Deeks, et al.
AIDS (London, England)|March 2, 2002
A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapyCalvin J Cohen, Susan Hunt, Michael Sension, et al.
Lancet (London, England)|July 19, 2011
Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trialCalvin J Cohen, Jaime Andrade-Villanueva, Bonaventura Clotet, et al.
Pharmacotherapy|February 26, 2008
Short-term safety and tolerability of a once-daily fixed-dose abacavir-lamivudine combination versus twice-daily dosing of abacavir and lamivudine as separate components: findings from the ALOHA studyCalvin J Cohen, Marshall Kubota, Philip S Brachman, et al.
BMC Musculoskeletal Disorders|March 3, 2010
Tai Chi for osteopenic women: design and rationale of a pragmatic randomized controlled trialPeter M Wayne, Julie E Buring, Roger B Davis, et al.
The Journal of Infectious Diseases|May 14, 2008
Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study, Sean Emery, Jacqueline A Neuhaus, et al.
Pageof 3